Recently, an oncolytic adenovirus expressing membrane-bound CD40L was evaluated in a preclinical setting as a treatment for pancreatic cancer, leading to tumor control via stimulation of human myeloid cells and T-cell responses [24]. This evidence concerns the gene CD40LG and neoplasm.